Neuroblastoma is a type of cancer that mostly affects young children. This study looks at a new way to treat high-risk neuroblastoma using a medicine called naxitamab along with regular chemotherapy. Chemotherapy is a treatment that uses powerful drugs to kill cancer cells. Naxitamab is a special medicine that helps the body's immune system fight cancer cells. The study involves 5 cycles of chemotherapy, and naxitamab is added to each cycle. Stem cell mobilization (a process to collect important blood cells) happens after the second cycle, and tumor surgery is planned after the fourth or fifth cycle. Researchers will check how well the treatment is working by measuring the cancer's response and watching for any side effects.

• The study requires several cycles of treatment and involves regular check-ups to monitor progress.
• Participants must be young (up to 21 years old) and meet specific health criteria to join the study.
• There are certain health risks and procedures involved, so it's important to consider them before joining.